Navigation Links
Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice,with Transplant of Purified Donor Blood Stem Cells

SAN CARLOS, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - Cellerant Therapeutics today announced the publication of data suggesting that established autoimmune disease can be reversed or stabilized by the transplantation of purified allogeneic (donated) hematopoietic (blood forming) stem cells (HSC) in a mouse study of Systemic Lupus Erythematosus (SLE). Subjects that underwent this procedure exhibited improved overall survival and decreased lupus symptoms. The research, led by Dr. Julie Christensen with colleagues from Cellerant and Stanford University, was published on April 13, 2007 as a First Edition Paper in the online version of the American Society of Hematology's journal, BLOOD (Smith-Berdan et. al., DOI 10.1182/BLOOD-2007-03-081497).

"The demonstration of successful reversal of the disease using purified stem cells with non-myeloablative conditioning offers a novel strategy to treat autoimmune diseases such as lupus with decreased morbidity," said Ramkumar Mandalam, Ph.D., Vice President of Pharmaceutical Operations. "This study also provides further support for our belief that purified stem cells may make it possible to use un-matched donors, such as a parent or non-identical sibling, for a variety of HSC treatment procedures."

"The publication of this preclinical data further validate Cellerant's unique use of pure hematopoietic stem cells for a wide range of therapeutic applications, including lupus and other autoimmune disorders, as well as for cancer and blood disorders," commented Bruce Cohen, Cellerant's President and CEO. "This finding is consistent with recent reports on successful use of hematopoietic stem cell transplantation for the treatment of autoimmune diseases and merits evaluation of pure stem cells in treating such diseases."

Cellerant researchers worked with specialized mice that are prone to an autoimmune condition that closely resembles human SLE. The study evaluated both
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:5/22/2013)... May 22, 2013  Flagship Ventures, a leading ... healthcare and sustainability, today announced the appointment of ... Senior Partner. In this role, Mr. Bancel will ... In addition to working closely with ... serves as President and Chief Executive Officer of ...
(Date:5/22/2013)... -- Grifols, a global healthcare company based in ... demonstrating that a higher dose of PROLASTIN © -C ... alpha 1 protein in patients with alpha 1 ... the normal range for healthy individuals. AAT deficiency is ... the alpha 1 proteinase inhibitor (A1PI) protein can ...
(Date:5/22/2013)... , May 22, 2013  Ohr Pharmaceutical Inc. ... of novel therapeutics for unmet medical needs, today announced ... , M.D., Ph.D., to its Board of Directors. Dr. ... on early and late stage drug development. ... Ohr,s Board," said Dr. Irach Taraporewala, CEO of Ohr ...
Breaking Medicine Technology:Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 2Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 3
... 15 ITelagen, Inc., innovative provider of healthcare ... Medical Services, Inc., a leading regional distributor of medical supplies, equipment ... today of the final rule on "meaningful use" of an electronic ... , , ...
... July 15 Merz Aesthetics today announced it is now shipping ... only available in Europe , Asclera™ was recently approved by the ... , , ... Phlebology , leading experts conclude that polidocanol is a highly effective ...
Cached Medicine Technology:Bell Medical and ITelagen Welcome Final Rule for 'Meaningful Use' of Electronic Health Records 2Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 2Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 3Merz Aesthetics™ Asclera™ (polidocanol) Injection Now Available in Doctors' Offices Nationwide 4
(Date:5/22/2013)... 22, 2013 A new study published online ... that of young people who visited fast food or chain ... were obese were more likely to use calorie information given ... found that young people eating at fast food or chain ... to use calorie information as those eating there once a ...
(Date:5/22/2013)... 2013 Nearly 50,000 veterans appeals were ... fiscal year 2012, with even more—54,033—expected by fiscal year-end ... a decision as the agency reports reduced decisions and ... veterans disability appeal services. The BVA is an ... Although the BVA received 49,611 cases in FY 2012, ...
(Date:5/22/2013)... People in the United States have been ... shortages. In much of the world, water shortages are normal ... Kleyne. She warns against taking water for granted and provides ... so easily in the United States. , Sharon Kleyne is ... show, heard live or by podcast on World Talk Radio, ...
(Date:5/22/2013)... 2013 According to a May 14, 2013 ... Options for Breast Cancer Surgery,” modern medical technology has given ... this disease in a whole new light. Since the new ... face breast cancer and mastectomies with greater hope ... the introduction of plastic surgery to oncology, women had little ...
(Date:5/22/2013)... (HealthDay News) -- Over the next two decades, the ... expected to more than double, topping more than $180 ... main factor driving the increase: an aging population. The ... American Stroke Association, was published May 22 in the ... the health care system," Dr. Bruce Ovbiagele, chairman of ...
Breaking Medicine News(10 mins):Health News:STRICTLY EMBARGOED UNTIL 6:00AM EST THURSDAY May 23, 2013; Calorie Information in Fast Food Restaurants Used by 40% of 9-18 Year Olds when Making Food Choices, Study Finds 2Health News:STRICTLY EMBARGOED UNTIL 6:00AM EST THURSDAY May 23, 2013; Calorie Information in Fast Food Restaurants Used by 40% of 9-18 Year Olds when Making Food Choices, Study Finds 3Health News:Veterans Disability Appeals See Fewer Decisions in FY2012, Reports Allsup 2Health News:Water Advocate Sharon Kleyne Announces Water Conservation Appreciation 2Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 3
... derived from a patient,s own bone marrow were safely used ... results of a Phase I clinical trial at The University ... were published in this month,s issue of Neurosurgery , ... data demonstrate that the acute harvest of bone marrow and ...
... During spring training, you will find Major League pitchers ... muscles to endure the grueling 162 game season. A ... journal of the Association for Psychological Science, suggests that ... could have on their brains. The study, led ...
... THURSDAY, March 10 (HealthDay News) -- New research challenges the ... animal species. It,s long been thought that humans, relatively ... people age more slowly than other animals. Comparisons with short-lived ... idea. But researchers who conducted the first-ever comparison of ...
... 9 (HealthDay News) -- The U.S. Food and Drug Administration on ... than 50 years when it approved Benlysta as a way to ... directly into a vein, Benlysta is the first drug designed to ... cells believed to be at the root of lupus, the FDA ...
... When prostate cancer stem cells (CSCs) were ... SAP stopped cancer stem cell colony formation and also ... (in vitro). According to the international team of researchers ... their results in a recent issue of Cell ...
... Hopkins Children,s Center researchers have discovered that most children ... The newly identified misalignment can affect how surgeries of ... researchers say. The study will be published ... Pediatric Orthopaedics . Previous studies of patients with ...
Cached Medicine News:Health News:Pitchers bean more batters in the heat of the summer 2Health News:Humans Age at Same Pace as Other Primates, Study Finds 2Health News:FDA Approves 1st New Lupus Drug in More Than 50 Years 2Health News:Trapping prostate cancer cells to keep them from spreading provides hope 2Health News:Hopkins Children's study finds some patients with cerebral palsy have asymmetric pelvic bones 2
... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
... Ultra thin collagen coated highly ... ultra thin wall construction offers ... The Hemacarotid UltraThin Patch provides ... conformability, and healing, without suture ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
... technology provides a rapid mechanical ... seal that protects and preserves ... plays a role in the ... compromise to the artery or ...
Medicine Products: